CN107890117A - A kind of compound oligomeric peptide nutrient powder of WPC - Google Patents
A kind of compound oligomeric peptide nutrient powder of WPC Download PDFInfo
- Publication number
- CN107890117A CN107890117A CN201710934686.5A CN201710934686A CN107890117A CN 107890117 A CN107890117 A CN 107890117A CN 201710934686 A CN201710934686 A CN 201710934686A CN 107890117 A CN107890117 A CN 107890117A
- Authority
- CN
- China
- Prior art keywords
- wpc
- parts
- powder
- oligopeptide
- wheat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 58
- 239000000843 powder Substances 0.000 title claims abstract description 37
- 235000015097 nutrients Nutrition 0.000 title claims abstract description 19
- 150000001875 compounds Chemical class 0.000 title claims abstract description 16
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 58
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 57
- 241000209140 Triticum Species 0.000 claims abstract description 50
- 235000021307 Triticum Nutrition 0.000 claims abstract description 50
- 229920002498 Beta-glucan Polymers 0.000 claims abstract description 37
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims abstract description 27
- 240000008042 Zea mays Species 0.000 claims abstract description 24
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 24
- 241000233866 Fungi Species 0.000 claims abstract description 23
- 239000012141 concentrate Substances 0.000 claims abstract description 20
- 239000002994 raw material Substances 0.000 claims abstract description 17
- WVXRAFOPTSTNLL-NKWVEPMBSA-N 2',3'-dideoxyadenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO)O1 WVXRAFOPTSTNLL-NKWVEPMBSA-N 0.000 claims abstract description 16
- 240000003394 Malpighia glabra Species 0.000 claims abstract description 16
- 235000014837 Malpighia glabra Nutrition 0.000 claims abstract description 16
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 claims abstract description 14
- 235000009973 maize Nutrition 0.000 claims abstract description 14
- 230000029087 digestion Effects 0.000 claims abstract description 8
- 150000001413 amino acids Chemical class 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 11
- 102000007544 Whey Proteins Human genes 0.000 claims description 10
- 108010046377 Whey Proteins Proteins 0.000 claims description 10
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 10
- 235000005822 corn Nutrition 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 9
- 108010068370 Glutens Proteins 0.000 claims description 8
- 235000021312 gluten Nutrition 0.000 claims description 8
- 229940088594 vitamin Drugs 0.000 claims description 8
- 229930003231 vitamin Natural products 0.000 claims description 8
- 235000013343 vitamin Nutrition 0.000 claims description 8
- 239000011782 vitamin Substances 0.000 claims description 8
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 8
- 235000021119 whey protein Nutrition 0.000 claims description 6
- 239000004383 Steviol glycoside Substances 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 229930182488 steviol glycoside Natural products 0.000 claims description 5
- 235000019411 steviol glycoside Nutrition 0.000 claims description 5
- 150000008144 steviol glycosides Chemical class 0.000 claims description 5
- 235000019202 steviosides Nutrition 0.000 claims description 5
- 239000005862 Whey Substances 0.000 claims description 4
- 238000001694 spray drying Methods 0.000 claims description 4
- 238000013329 compounding Methods 0.000 claims description 3
- 238000002955 isolation Methods 0.000 claims description 3
- 238000000108 ultra-filtration Methods 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 abstract description 37
- 230000035764 nutrition Effects 0.000 abstract description 33
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 abstract description 24
- 206010028980 Neoplasm Diseases 0.000 abstract description 22
- 210000004369 blood Anatomy 0.000 abstract description 21
- 239000008280 blood Substances 0.000 abstract description 21
- 201000010099 disease Diseases 0.000 abstract description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 19
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract description 9
- 208000002720 Malnutrition Diseases 0.000 abstract description 7
- 208000025865 Ulcer Diseases 0.000 abstract description 6
- 230000002708 enhancing effect Effects 0.000 abstract description 6
- 230000001071 malnutrition Effects 0.000 abstract description 6
- 235000000824 malnutrition Nutrition 0.000 abstract description 6
- 208000015380 nutritional deficiency disease Diseases 0.000 abstract description 6
- 230000002829 reductive effect Effects 0.000 abstract description 6
- 208000024891 symptom Diseases 0.000 abstract description 6
- 231100000397 ulcer Toxicity 0.000 abstract description 6
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 5
- 230000036541 health Effects 0.000 abstract description 5
- 208000015181 infectious disease Diseases 0.000 abstract description 5
- 230000000968 intestinal effect Effects 0.000 abstract description 5
- 230000009286 beneficial effect Effects 0.000 abstract description 4
- 206010029164 Nephrotic syndrome Diseases 0.000 abstract description 2
- 230000005784 autoimmunity Effects 0.000 abstract description 2
- 208000019423 liver disease Diseases 0.000 abstract description 2
- 208000009928 nephrosis Diseases 0.000 abstract description 2
- 231100001027 nephrosis Toxicity 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 78
- 230000000694 effects Effects 0.000 description 61
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 53
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 37
- 229930003268 Vitamin C Natural products 0.000 description 37
- 235000019154 vitamin C Nutrition 0.000 description 37
- 239000011718 vitamin C Substances 0.000 description 37
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 36
- 230000006870 function Effects 0.000 description 33
- 235000018102 proteins Nutrition 0.000 description 33
- 108090000623 proteins and genes Proteins 0.000 description 33
- 102000004169 proteins and genes Human genes 0.000 description 33
- 102000004407 Lactalbumin Human genes 0.000 description 27
- 108090000942 Lactalbumin Proteins 0.000 description 27
- 229960003180 glutathione Drugs 0.000 description 26
- 108010035532 Collagen Proteins 0.000 description 25
- 102000008186 Collagen Human genes 0.000 description 24
- 229920001436 collagen Polymers 0.000 description 24
- 238000011160 research Methods 0.000 description 24
- 230000015572 biosynthetic process Effects 0.000 description 20
- 150000004676 glycans Chemical class 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 19
- 235000013305 food Nutrition 0.000 description 19
- 229920001282 polysaccharide Polymers 0.000 description 19
- 239000005017 polysaccharide Substances 0.000 description 19
- 239000000047 product Substances 0.000 description 18
- 150000003254 radicals Chemical class 0.000 description 17
- 238000003786 synthesis reaction Methods 0.000 description 17
- 235000012000 cholesterol Nutrition 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 208000027418 Wounds and injury Diseases 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 15
- 230000003078 antioxidant effect Effects 0.000 description 15
- 235000019197 fats Nutrition 0.000 description 15
- 239000003963 antioxidant agent Substances 0.000 description 14
- 210000004185 liver Anatomy 0.000 description 14
- 235000006708 antioxidants Nutrition 0.000 description 13
- 201000011510 cancer Diseases 0.000 description 13
- 241001506047 Tremella Species 0.000 description 11
- 206010052428 Wound Diseases 0.000 description 11
- 230000006378 damage Effects 0.000 description 11
- 238000010521 absorption reaction Methods 0.000 description 10
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 9
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 9
- 230000035876 healing Effects 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 210000002784 stomach Anatomy 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 229920001503 Glucan Polymers 0.000 description 8
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 230000003064 anti-oxidating effect Effects 0.000 description 8
- 239000000306 component Substances 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 230000036039 immunity Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 230000029663 wound healing Effects 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 208000024172 Cardiovascular disease Diseases 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 230000033228 biological regulation Effects 0.000 description 7
- 230000036772 blood pressure Effects 0.000 description 7
- 210000002540 macrophage Anatomy 0.000 description 7
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 6
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 230000000050 nutritive effect Effects 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 101800001982 Cholecystokinin Proteins 0.000 description 5
- 102100025841 Cholecystokinin Human genes 0.000 description 5
- 208000004930 Fatty Liver Diseases 0.000 description 5
- 206010019708 Hepatic steatosis Diseases 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 5
- 102000007330 LDL Lipoproteins Human genes 0.000 description 5
- 108010001831 LDL receptors Proteins 0.000 description 5
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 5
- 208000034189 Sclerosis Diseases 0.000 description 5
- 206010047623 Vitamin C deficiency Diseases 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 229940107137 cholecystokinin Drugs 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 208000010706 fatty liver disease Diseases 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 208000010233 scurvy Diseases 0.000 description 5
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 5
- 231100000240 steatosis hepatitis Toxicity 0.000 description 5
- LGQKSQQRKHFMLI-SJYYZXOBSA-N (2s,3r,4s,5r)-2-[(3r,4r,5r,6r)-4,5,6-trihydroxyoxan-3-yl]oxyoxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)CO[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)OC1 LGQKSQQRKHFMLI-SJYYZXOBSA-N 0.000 description 4
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 4
- 102100029077 3-hydroxy-3-methylglutaryl-coenzyme A reductase Human genes 0.000 description 4
- LGQKSQQRKHFMLI-UHFFFAOYSA-N 4-O-beta-D-xylopyranosyl-beta-D-xylopyranose Natural products OC1C(O)C(O)COC1OC1C(O)C(O)C(O)OC1 LGQKSQQRKHFMLI-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 241000186000 Bifidobacterium Species 0.000 description 4
- SQNRKWHRVIAKLP-UHFFFAOYSA-N D-xylobiose Natural products O=CC(O)C(O)C(CO)OC1OCC(O)C(O)C1O SQNRKWHRVIAKLP-UHFFFAOYSA-N 0.000 description 4
- 108010024636 Glutathione Proteins 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 4
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- 108010063045 Lactoferrin Proteins 0.000 description 4
- 102000010445 Lactoferrin Human genes 0.000 description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 235000019789 appetite Nutrition 0.000 description 4
- 230000036528 appetite Effects 0.000 description 4
- 239000003613 bile acid Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
- 230000002440 hepatic effect Effects 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 229960002591 hydroxyproline Drugs 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 4
- 229940078795 lactoferrin Drugs 0.000 description 4
- 235000021242 lactoferrin Nutrition 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 150000002978 peroxides Chemical class 0.000 description 4
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 230000005778 DNA damage Effects 0.000 description 3
- 231100000277 DNA damage Toxicity 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 241000194033 Enterococcus Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 108010073771 Soybean Proteins Proteins 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000003183 carcinogenic agent Substances 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229960001231 choline Drugs 0.000 description 3
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical group C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000009931 harmful effect Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- -1 lactoalbumin Proteins 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 238000005502 peroxidation Methods 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000036186 satiety Effects 0.000 description 3
- 235000019627 satiety Nutrition 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 235000019710 soybean protein Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 102000008490 2-Oxoglutarate 5-Dioxygenase Procollagen-Lysine Human genes 0.000 description 2
- 108010020504 2-Oxoglutarate 5-Dioxygenase Procollagen-Lysine Proteins 0.000 description 2
- JCSJTDYCNQHPRJ-UHFFFAOYSA-N 20-hydroxyecdysone 2,3-acetonide Natural products OC1C(O)C(O)COC1OC1C(O)C(O)C(OC2C(C(O)C(O)OC2)O)OC1 JCSJTDYCNQHPRJ-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 229940123457 Free radical scavenger Drugs 0.000 description 2
- 108010063907 Glutathione Reductase Proteins 0.000 description 2
- 102000006587 Glutathione peroxidase Human genes 0.000 description 2
- 108700016172 Glutathione peroxidases Proteins 0.000 description 2
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 2
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 2
- 208000034767 Hypoproteinaemia Diseases 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 102000002070 Transferrins Human genes 0.000 description 2
- 108010015865 Transferrins Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000002929 anti-fatigue Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- JCSJTDYCNQHPRJ-FDVJSPBESA-N beta-D-Xylp-(1->4)-beta-D-Xylp-(1->4)-D-Xylp Chemical compound O[C@@H]1[C@@H](O)[C@H](O)CO[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)C(O)OC2)O)OC1 JCSJTDYCNQHPRJ-FDVJSPBESA-N 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000008717 functional decline Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000030136 gastric emptying Effects 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 230000007661 gastrointestinal function Effects 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 235000020688 green tea extract Nutrition 0.000 description 2
- 238000001631 haemodialysis Methods 0.000 description 2
- 230000000322 hemodialysis Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 2
- 238000005805 hydroxylation reaction Methods 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 208000021822 hypotensive Diseases 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000035992 intercellular communication Effects 0.000 description 2
- 239000010977 jade Substances 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000002366 mineral element Substances 0.000 description 2
- 235000008935 nutritious Nutrition 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 230000008855 peristalsis Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000000291 postprandial effect Effects 0.000 description 2
- 230000002633 protecting effect Effects 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000019635 sulfation Effects 0.000 description 2
- 238000005670 sulfation reaction Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 229920001221 xylan Polymers 0.000 description 2
- 150000004823 xylans Chemical class 0.000 description 2
- ABKNGTPZXRUSOI-UHFFFAOYSA-N xylotriose Natural products OCC(OC1OCC(OC2OCC(O)C(O)C2O)C(O)C1O)C(O)C(O)C=O ABKNGTPZXRUSOI-UHFFFAOYSA-N 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- TWNIBLMWSKIRAT-RWOPYEJCSA-N (1r,2s,3s,4s,5r)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol Chemical compound O1[C@@]2([H])OC[C@]1([H])[C@@H](O)[C@H](O)[C@@H]2O TWNIBLMWSKIRAT-RWOPYEJCSA-N 0.000 description 1
- GDSOZVZXVXTJMI-SNAWJCMRSA-N (e)-1-methylbut-1-ene-1,2,4-tricarboxylic acid Chemical compound OC(=O)C(/C)=C(C(O)=O)\CCC(O)=O GDSOZVZXVXTJMI-SNAWJCMRSA-N 0.000 description 1
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 1
- HVYWMOMLDIMFJA-UHFFFAOYSA-N 3-cholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 HVYWMOMLDIMFJA-UHFFFAOYSA-N 0.000 description 1
- 101710158485 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000012639 Balance disease Diseases 0.000 description 1
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- XJECNSWAHCMYNZ-UHFFFAOYSA-N C=C.[Fe].[Na] Chemical group C=C.[Fe].[Na] XJECNSWAHCMYNZ-UHFFFAOYSA-N 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102000010970 Connexin Human genes 0.000 description 1
- 108050001175 Connexin Proteins 0.000 description 1
- 102000001045 Connexin 43 Human genes 0.000 description 1
- 108010069241 Connexin 43 Proteins 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108010001817 Endo-1,4-beta Xylanases Proteins 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 101000693916 Gallus gallus Albumin Proteins 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 241000726221 Gemma Species 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000988577 Homo sapiens 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 description 1
- 101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010021518 Impaired gastric emptying Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 108010061951 Methemoglobin Proteins 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 102000004079 Prolyl Hydroxylases Human genes 0.000 description 1
- 108010043005 Prolyl Hydroxylases Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000003286 Protein-Energy Malnutrition Diseases 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 241000508269 Psidium Species 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 206010049416 Short-bowel syndrome Diseases 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 108010056079 Subtilisins Proteins 0.000 description 1
- 102000005158 Subtilisins Human genes 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241000908178 Tremella fuciformis Species 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000009858 acid secretion Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002804 anti-anaphylactic effect Effects 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229940004120 bifidobacterium infantis Drugs 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 230000003130 cardiopathic effect Effects 0.000 description 1
- 230000036996 cardiovascular health Effects 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000008358 core component Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000005906 dihydroxylation reaction Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000005782 double-strand break Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 231100000880 dysequilibrium Toxicity 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229910001447 ferric ion Inorganic materials 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000021022 fresh fruits Nutrition 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 210000003976 gap junction Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 108010050792 glutenin Proteins 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000000640 hydroxylating effect Effects 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 108010062951 hypertensive factor Proteins 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 231100000405 induce cancer Toxicity 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000003212 lipotrophic effect Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000020442 loss of weight Diseases 0.000 description 1
- 235000015263 low fat diet Nutrition 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 235000020905 low-protein-diet Nutrition 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000004682 mucosal barrier function Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- HLNRBHDRGMNBEG-UHFFFAOYSA-N nitrous acid Chemical compound ON=O.ON=O HLNRBHDRGMNBEG-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000001451 organic peroxides Chemical class 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 210000001819 pancreatic juice Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000006555 post-translational control Effects 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 238000001814 protein method Methods 0.000 description 1
- 235000020826 protein-energy malnutrition Nutrition 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 210000000515 tooth Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
- A23L31/10—Yeasts or derivatives thereof
- A23L31/15—Extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
It is main to include following raw material in parts by weight the invention discloses a kind of compound oligomeric peptide nutrient powder of WPC:55~70 parts of WPC, 7~12 parts of white fungus powder, 7~12 parts of acerola concentrate powder, 2~6 parts of wheat oligopeptide, 2~6 parts of maize oligopeptide, 0.5~1.7 part of yeast beta glucan, 3~6 parts of xylo-oligosaccharide.Beneficial effects of the present invention are:Compatibility of the present invention is scientific and reasonable, and Synergistic, improve clinical malnutrition symptom from different perspectives, solve the problems, such as nutrition digestion and absorb, promote the rehabilitation of the patients such as operation, ulcer, and can improves function of intestinal canal, enhancing autoimmunity, and can improve blood health, the incidence of infection risk and complication is reduced, is adapted to the professional Medical Degree of a variety of diseases such as diabetes, nephrosis, hepatopathy, tumour, chemicotherapy, angiocardiopathy, burn, infection.
Description
Technical field
The present invention relates to food processing technology field, mainly a kind of compound oligomeric peptide nutrient powder of WPC.
Background technology
In recent years, China pays much attention to the development of clinical nutrition industry, is put into effect in 2013《Special medicine purposes formula is eaten
Product general rule》, the legal status of clear and definite special medicine purposes formula food (FSMP), and implementing on July 1st, 2016 first《It is special
Different medical usage formula food registration management method》.Clinical nutrition plays an important role during disease is treated, Huan Zheying
The quality for the situation of supporting directly affects the healing of wound and the recovery of disease, and the generation of some diseases can be delayed by being in a good state of nutrition
And development.
Clinical nutrition, refer to treat or alleviating disease, strengthen the clinical effectiveness for the treatment of, and taken according to nutrition principle
Diet nutritional measure.Professional Medical Degree method is broadly divided into parenteral and two kinds of approach of enteral.Enteral nutrition is carried through intestines and stomach
The nutriment and the nutritional support mode of other various nutrients needed for metabolism, it is desirable to which patient's functions of intestines and stomach is strong fully or partially
It is sound.Enteral nutrition preparation can be divided into by balance can provide the balance preparation of nutriment needed by human comprehensively, for certain
The disease that kind specified disease or special population digest feature and required nutrition and prepared is using type preparation and only with certain or certain class
Assembly type preparation based on nutrient.Enteral nutrition preparation can be divided into whole protein type, short peptide type and amino acid pattern by nitrogen source, can be with
Ensure that the different patient of functions of intestines and stomach can effectively carry out digesting and assimilating protein and other nutriments.
Abroad, clinical nutrition has had the developing history of more than 50 years, has developed relative maturity, clinical nutrition conduct
Medical assistance means can effectively support the treatment and recovery of patient.2014, global clinical nutritive preparations market scale was
38900000000 dollars, nearly 4 years average growth rates per annum are stable in 6-7%, and gradually tend towards stability.Wherein U.S. European market accounts for the whole world
Market more than half, Japanese market scale is maximum in the Asian-Pacific area, account for the whole world 20% or so, and other Asian-Pacific countries
Clinical nutritive preparations consumption is less.China is influenceed by overall clinical diagnostic level at present, and medical field is with masses to clinical nutrition
The degree of awareness and usage degree are relatively low.The time for causing professional Medical Degree to be carried out extensively is shorter, Clinical Nutrition
Build and the application of clinical nutrition is still in the initial stage explored and developed, China's generally existing patient shortage is effective at present
Nutrition treatment situation.
In recent years, clinical nutrition market in China's kept relatively stable quickly growth, according to Beijing Guo Yan CTC (Centell Technology Corporation) economic information
Referral centre's survey data shows, 2014, and China's clinical nutrition products market scale is 115.5 hundred million yuan, nearly 4 years average annual
Increasing stable 18% or so, enteral nutrition scale 2,900,000,000 or so, compound speedup is more than 30% in recent years, accounting only four/
One, product structure difference is huge compared with external enteral nutrition accounting is more than 80% for this, and following enteral nutrition will keep quick
Increase.
The common product in market is mostly to provide protein and other basal nutrients element, and most of product has compounded soybean egg
In vain, the biological value of soybean protein is not as good as lactalbumin, and more not as good as oligopeptide preparation, absorbing, aspect is not ideal enough.In addition,
Clinically there is great demand to lifting immune, promotion wound healing, improving gastrointestinal function etc., and existing market is most
Product can not all meet, and mouthfeel is poor, and user's compliance is bad.The present invention in view of the above-mentioned problems, carried out clinical investigations,
The nutrient formulation of science is devised, perfection solves the above problems.
The content of the invention
It is an object of the invention to overcome the shortcomings of the prior art, and it is compound oligomeric to provide a kind of WPC
Peptide nutrient powder.
The purpose of the present invention is completed by following technical solution.This compound oligopeptide nutrition of WPC
Powder, it is main to include following raw material in parts by weight:55~70 parts of WPC, 7~12 parts of white fungus powder, acerola concentrate powder
7~12 parts, 2~6 parts of wheat oligopeptide, 2~6 parts of maize oligopeptide, 0.5~1.7 part of yeast-beta glucan, xylo-oligosaccharide 3~6
Part.
The present invention is (dense by native whey protein made of low temperature ultrafiltration and spray drying by whey with WPC
Contracting thing, the product contain lecithin.It has high nutritive value, is movement nutrition food and other protein fortification formulas food
The desirable feedstock of product.Its wetability is good in cold water and warm water, and dissolving is rapid.), white fungus powder (it is extracted, concentration, dry
It is refined to form), acerola concentrate powder (extracted, concentration, drying refined form), wheat oligopeptide (using Gluten as raw material, pass through
The micromolecule polypeptide class mixture of digestion and the acquisition of specific small peptide isolation technics is oriented, main component is by 2~6 amino acid
Molecule form small peptide), maize oligopeptide (a series of product after enzymolysis, it is made up of a large amount of small-molecular-weight small peptides,
Molecular weight concentrates on less than 1000), yeast-beta glucan (using saccharomyces cerevisiae as raw material, the processing of extracted, soda acid, spray drying
Produced etc. step), xylo-oligosaccharide (steam explosion or autoclaving are used as raw material using wheat stalk or maize straw
Method, produced through zytase enzymolysis) it is raw material, it is well mixed with equivalent principle of progressively increasing.
Beneficial effects of the present invention are:The present invention is using lactalbumin as core, there is provided high-quality protein nutritive, compounding wheat are low
Poly- peptide and maize oligopeptide, can directly absorb, and transport speed is fast, power consumption is low, is not easy saturation, while can eliminate and free ammonia
The absorption competition of base acid, the characteristics of making up not available for whey protein and amino acid;And acerola concentrate is natural complex C
Source, for the amino acid after digesting and assimilating, small peptide synthesis collagen can be promoted herein, recover to have greatly for postoperative wound
Benefit;White fungus powder is then rich in polysaccharide component, can be promoted wound healing with renovating tummy mucous membrane, can be helped digest gastrointestinal hemorrhage and operation
The recovery of crowd, improve the digestion and absorption function of disease of stomach patient;Yeast-beta glucan can allow food stickiness increase, gastric emptying
Speed slow down, and then satisfaction when adding dining and postprandial satiety can also stimulate cholecystokinin (CCK)
Release, improve human consumption's absorption function, and stimulate the effect of small bowel peristalsis;Xylo-oligosaccharide has very strong propagation enteron aisle prebiotic
The function of bacterium, there is high selectivity cultivation effect to probiotics such as Bifidobacterium, lactic acid bacterias, but to Escherichia coli, enterococcus, fusiform
The pathogens such as bacillus then have obvious inhibitory action, improve function of intestinal canal comprehensively, improve constipation and symptom of diarrhea.The present invention
Compatibility is scientific and reasonable, and Synergistic, improves clinical malnutrition symptom from different perspectives, that is, solves nutrition digestion and absorption
The problem of, promote the rehabilitation of the patients such as operation, ulcer, and can improves function of intestinal canal, enhancing autoimmunity, and can improve blood
Health, the incidence of infection risk and complication is reduced, be adapted to diabetes, nephrosis, hepatopathy, tumour, chemicotherapy, cardiovascular disease
The professional Medical Degree of a variety of diseases such as disease, burn, infection.
The present invention is reconstituted food, and uniformly (market like product reconstitutes unites rapid dispersion energy more, less soluble in water
Solution), it is convenient to take.It is adapted to appetite low or has feed difficulty and the unsound crowd of digestive function to take, absorbs quick, battalion
Support and enrich, effect is unique, and after different case study on implementation are made, mouthfeel is excellent, greatly promotes the compliance for the crowd of taking, same compared with market
Class product has obvious advantage.
Embodiment
Detailed introduction is done to the present invention below in conjunction with embodiment:
The compound oligomeric peptide nutrient powder of this WPC of the present invention, it is main include it is following in parts by weight
Raw material:55~70 parts of WPC, 7~12 parts of white fungus powder, 7~12 parts of acerola concentrate powder, 2~6 parts of wheat oligopeptide, jade
2~6 parts of oligopeptide of rice, 0.5~1.7 part of yeast-beta glucan, 3~6 parts of xylo-oligosaccharide.Not only containing abundant adequate proteins battalion
Support, also compounded the multiple functions factor, predominantly the crowd such as Hypoproteinemia, malnutrition, hypoimmunity offer is high-quality can
The nutritional support leaned on.The specific requirement of each raw material see the table below.
Material name | Index components | Quality requirement |
WPC | Protein | >=80% |
White fungus powder | Polysaccharide | >=30% |
Acerola concentrate powder | Vitamin C | >=5% |
Wheat oligopeptide | Protein, oligopeptide | Protein >=90%, oligopeptide >=75% |
Maize oligopeptide | Protein, oligopeptide | Protein >=80%, oligopeptide >=75% |
Yeast-beta glucan | Beta glucan | >=80% |
Xylo-oligosaccharide | Xylo-oligosaccharide | >=95% |
The mechanism of the present invention:
1 WPC and its function
Lactalbumin is considered as " king of albumen " in nutrition, is the main component of lactoprotein, is needed rich in human body
All essential amino acids.It is more containing bioactivity with purity height, amino acid ligand than appropriately, being easily digested
Peptide, such as many advantages, such as lactoglobulin, lactoalbumin, immunoglobulin, lactoferrin and multiple polypeptides, it can effectively improve nutrition
Situation, it is the best source that clinical various Therapeutic diets or pipe feed diet good protein.WPC used in the present invention
It is that whey is contained into lecithin by native whey protein concentrate (WPC), the product made of low temperature ultrafiltration and spray drying.It
It is the desirable feedstock of movement nutrition food and other protein fortification formula foods with high nutritive value.In cold water and
Its wetability is good in warm water, and dissolving is rapid.
1.1 maintain and improve immunity of organisms
Research confirms that nutrition has a major impact to immunity function, and lactalbumin improves reduced glutathione (GSH) water
Flat, help maintains and improved immunity.GSH is that immune system needs antioxidant, can cause its decline in disease.Lactalbumin
Good nutrition is kept, disease treatment and rehabilitation is reached optimum state.
1.2 Green Tea Extracts, anti-aging
Lactalbumin includes lactoferrin, promotes oxygenation and to Green Tea Extract.Lactoferrin is transferrins family
Member.Transferrins produces energy and regulation and control red blood cell, hemoglobin generation.
1.3 maintain renal function
End-stage renal failure protein malnutrition is fairly common, and 6%~8% maintenance hemodialysis have severe malnutrition,
33% has mild to moderate malnutritive.Before chronic renal failure dialysis, more strict control protein intakes, long-term low protein diet, urine
Protein lost, final serious protein malnutrition, histone, which decomposes, to be accelerated, and is dead major reason.Maintenance dialysis is because of generation
Thank with endocrine disturbance, poor appetite and nausea and vomiting, nutrient malabsorption, dialyse insufficient, adverse reaction and loss etc., have
Obvious nutrition intake deficiency and loss, cause albumen synthesis to reduce and decompose increase.Hemodialysis can induce catabolism and accelerate.Therefore into
Year dialysis person's food proteins demand is higher than average adult.
1.4 promote wound healing
Body injury and wound healing need enough high quality protein matter, and it is thing necessary to epithelial growth is repaired
Matter.Protein insufficiency of intake, or the low healing that can all extend damage of intake quality, or even disunion.Lactalbumin is high-quality egg
In vain, its biological utilisation valency highest, it is the protein that override uses in burn and surgical intervention.Lactoferrin can adjust immune
Reaction, protection is provided for postoperative patient.After short bowel syndrome gives whey protein preparation, the healing of wound can be promoted.
1.5 preventing and treatings " four high diseases "
Prevent and treat hyperglycemia:Lactalbumin contains abundant leucine (Leu), can stimulate insulin secretion, effectively utilize itself
Insulin, control blood glucose.Diabetic is general, and appetite is good, after eating lactalbumin, energy dust satiety, can reduce " more than three
One is few " symptom.While balanced appropriate good protein is provided for patient, excessive energy will not be absorbed, and improve blood glucose
And symptom management, delay and prevent the occurrence and development of complication.
Prevent and treat hypertension:High blood pressure is most commonly seen in angiocardiopathy, because that can cause atherosclerosis, then makes
Blood vessel elasticity declines, and luminal stenosis, causes the vitals hypoxic-ischemic such as heart, brain, turns into the main danger of cardiovascular and cerebrovascular diseases
Dangerous factor.Lactalbumin is hyperpietic's optimum protein matter complementary goods, and to lowering blood pressure, reducing complication has positive role.
Prevent and treat high fat of blood:Hyperlipidemia shows as a variety of lipid concentrations of blood plasma and exceeded normally.With the improvement of living standards,
Hyperlipidemia turns into one of risk factors of cardiovascular diseases.Hyperlipidemia, will not be because of Energy intaking when supplementing lactalbumin
It is excessive and cause overweight or fat, it also will not increase cholesterolemia because saturated fat is excessive, be advantageous to hyperlipidemia patient
Blood fat is reduced, prevents the generation of complication.
1.6 fat-reducing
Lactalbumin is practically free of fat and carbohydrate, is low energy or low fat diet.High quality lactalbumin is containing rich
Rich leucine (Leu) reduces Fatty synthesis to protect thin body tissue.Lactalbumin contains more than Chicken Albumin and soybean protein
Leu.Absorbed by slowing down blood glucose, stabilizing blood sugar, reduce insulin, reduce hunger, make body be easier to produce using fat
Energy.Lactalbumin is added, Avoirdupois monitoring has significant difference, and lactalbumin can promote loss of weight and maintain standard weight.
1.7 preventing and treating cardiovascular and cerebrovascular diseases
The hazards for most influenceing cerebrovascular disease incidence of disease are hypertension and high fat of blood, and Whey protein active peptide can be with
Reduce these hazards harmful effects.Its antioxidation, protects cardiovascular health on the whole, improves cardiovascular machine
Can, prevention of cardiovascular disease.
1.8 preventing and treating fatty livers
The major organs that liver is neutral fat synthesis, transports and utilize, Fatty synthesis and transhipment dysequilibrium, then it is fatty
Fatty liver is piled into liver.Phosphatide be synthesis lipoprotein essential material, as phosphatide decline or synthetic phospholipid insufficient raw material, especially
It is choline or participates in synthesis choline methionine deficiency, influences synthesis and output of the lipoprotein in liver, form fatty liver.Research card
Bright, it is to form fatty liver common cause that long-term height is sugared, higher fatty acid and fat.Lactalbumin provides protein raw materials for liver, in medicine
Thing treatment can promote liver cell recovery and new life simultaneously, prevent from being denatured necrosis of liver cells and developing into hepatic sclerosis.Its low fat
Content can reduce liver and fat metabolism is born, and be Patients with Fatty Liver ideal protein food.
1.9 preventing and treating hepatic sclerosis
Hepatic sclerosis is a variety of causes for a long time or damages liver repeatedly and cause Diffuse fibrous hyperblastosis and liver cell nodules
Shape is regenerated, and liver normal configuration is destroyed, and forms the serious disease that liver is hardened.Medical evidence, protein and choline are lacked in food
During energy lipotropic factor, liver can be damaged and induce hepatic sclerosis.Lactalbumin matter containing high quality protein, meeting patient to excellent
Will not be excessive because of fat intake during matter albumen demand, more than liver metabolism ability, make fat deposition cause liver function to enter in liver
One step is damaged, and serum protein content is relatively low and has the patient of ascites, there is provided high-quality protein is even more important.
1.10 prevent and treat peptic ulcer
Protein is the raw material of histocyte reparation, and only sufficient albumen ulcer surface could be repaired.Lactalbumin is ulcer
Good source is repaired in face, can quickly promote the healing of ulcer surface, and protection gastric mucosal barrier is without prejudice, enhancing stomach lining resistance
Power, while albumen intake plays cushioning effect to hydrochloric acid in gastric juice again, promotes ulcer surface healing while stomach metabolism burden is not increased.
1.11 contribute to cancer patient's rehabilitation
Cancer patient is in chemotherapy or Patients During Radiotherapy, often because Nausea and vomiting and the factor such as be off one's feed, make daily
The subalimentation of intake, cause Body weight loss, musculature is lost and protein-energy malnutrition.Lactalbumin Yin Qiyi
The advantages of digesting, be non-stimulated to body, is the good source of cancer patient's protein.Supplement lactalbumin can maintain the high GSH of cell
Concentration and raising cellular anti-oxidant defence capability, to promote to carcinogenic substance detoxication.Shown in animal and Vitro Experimental Results,
Lactalbumin can suppress some cancer cells and increase, such as prostate cancer, breast cancer, colon cancer.Compared with feeding casein rat,
Feeding lactalbumin rat tumor incidence reduces nearly 50%;Compared with feeding soybean protein, obvious reduce occurs for tumour.Whey
The ability of chelates ferric ions contributes to anticancer.Mechanism of action is that lactalbumin has very strong anti-oxidative activity, because cysteine
(Cys) content height contributes to GSH to synthesize, and GSH is generally acknowledged intracellular powerful antioxidant.Cys contains sulfydryl, plays reducing agent work
With, prevent cell tissue aoxidize and damage.Antioxidant GSH effects in its reduction-state are most strong.Lactalbumin can directly be used
Intracellular GSH is improved as Cys sources.
1.12 contribute to HIV therapy
Trophism adaptive immune shortage syndrome (HIV) that be malnutritive and causing immune dysfunction, which has caused, generally to be weighed
Depending on being increasingly becoming for important nutrient protein necessary to humans and animals and amino acid with animal body immunity function relation
The emphasis of research.The research for carrying out auxiliary treatment to HIV with the pure lactalbumin of separation is prompted, and the HIV of the obvious deficiencies of GSH is suffered from
Person, give rich in Cys lactalbumins, significantly and serum GSH levels can be continued to increase after 6 months, and can reach normal level.It is logical
Normal HIV Patient cells GSH contents reduce, and high-level GSH substantially slows down virus replication, caused under virus activity substance
Drop, increase the HIV survival of patients time limits.
2 white fungus and its function
White fungus (Tremella fuciformis) is nutritious, and food flavor is delicious, not the still very high edible mushroom of nutritive value,
And the higher medicinal fungus of medical value, it is universally acknowledged health products.China's white fungus aboundresources, it is provided with for development and application white fungus
Sharp condition.As cultivating white fungus industry develops rapidly and application is widened, to white fungus nutritional ingredient and in medical care effect side
Face research is also progressively goed deep into.Tremella polysaccharides (Tremella polysaccharides, TP) is white fungus important activity composition, its work(
Energy characteristic increasingly attracts attention.
2.1 immunological regulations, antitumor action
For many years, scientists find that tremella polysaccharides take part in the regulation of the various biological phenomenas of cell, such as immunocyte
Between the transmission and impression of information, immune cell activated and immunologic function etc. for improving body.By this participation, tremella polysaccharides is not
Antitumor action only can be played by enhancing host immune function, moreover it is possible to swollen by directly acting on tumour cell or induction
The approach direct killing tumour cell such as apoptosis of tumor.
2.2 hypoglycemic, effect for reducing blood fat
There are some researches show tremella polysaccharides can adjust the activity of glycometabolism enzyme, promote islet secretion insulin to suppress sugar different
It is raw, promote utilization of the peripheral tissues to glucose, it is hypoglycemic so as to have the function that.Tremella polysaccharides can be by fettering and adsorbing
Lipid promotes cholesterol discharge in blood, blocks it in hepato-enteric circulation, reaches the effect for reducing blood fat.
2.3 prevention and cure of cardiovascular disease
Research shows that tremella polysaccharides can be obviously prolonged the formation time of thrombus, and reducing blood platelet, suddenly attached rate and blood are suddenly spent,
Have the function that prevention and cure of cardiovascular disease.
2.4 antiulcer action
Tremella polysaccharides can substantially suppress the formation of stress in rats type gastric ulcer, promote the healing of acetic acid type gastric ulcer, to stomach
Acid secretion and pepsin activity have no influence.124 observation of curative effect of duodenal ulcer are treated using tremella polysaccharides, are had in the recent period
Efficiency is up to 98.6%, and recent healing rate is up to 79.03%.
2.5 anticoagulations, promote wound healing and effect
Tremella polysaccharides can by influenceing intrinsic coagulation system, prolongation thrombin time and realize blood coagulation resisting function.
In addition, tremella polysaccharides has the protection surface of a wound, prevention infection effect to tested rat wound, wound can be made suitable along physiology reparation approach
Profit is carried out, so as to reach the effect of I phase healing
3 acerola concentrates and its effect
After acerola concentrate is found the every 100 grams vitamin Cs containing 1800~4000mg superelevation amounts from nineteen forty-six, cause section
Educational circles greatly pays close attention to.Acerola concentrate is Vitamin C content highest in the plant planted at present, and Vc content is in every 100g fruits
35 times of lemon, 17 times of strawberry, also the guava more high than being considered as vitamin C is high 11 times, is qualified " vitamin
C king ", while be also the weight for maintaining human life integral containing the elements such as dimension A, dimension B1, dimension B2, iron, calcium, vitamin C
Composition is wanted, the function with preventing and treating bad hematic acid, is a kind of water miscible dimension so being called ascorbic acid (ascorbic acid)
Raw element.It anti-can catch a cold, anti-scurvy, improves human body resistivity, has certain effect to beauty and cancer.Health care,
It is widely used in terms of beverage, beauty.
3.1 anti-oxidant and effect of scavenging radical
Free radical (free radical) is harmful substance caused by body reaction, has very strong oxidisability, can damage
The tissue and cell of body, so as to cause a series of chronic disease.Vitamin C is a kind of water miscible free radical scavenger,
OH, R and O can be removed in vivo2-Deng free radical, played an important role in anti-oxidant.Glutathione
(glutathione, GSH) is the small peptide material containing sulfydryl, has the function that anti-oxidant and removing toxic substances.GSH has reduced form (G-
SH) and two kinds of forms of oxidized form (G-S-S-G), wherein glutathione reductase (glutathione reductase) are catalyzed two
Mutual conversion between kind material.In body, many protein containing sulfydryl and enzyme need sulfydryl (- SH) competence exertion
Effect, and sulfydryl is easily aoxidized by such as some harmful substances such as free radical H2O2 so that cell damage, be metabolized in vivo by
Resistance etc..GSH itself can be protected other albumen and enzyme to exempt from the destruction of free radical, played oxidation resistant work by free-radical oxidation
With.GSH content is more in internal red blood cell, and GSH can protect the sulfydryl of the albumen on erythrocyte membrane to be in reduction-state, preventing and treating
Haemolysis;Hemoglobin can be protected, prevent hemoglobin by free radical with peroxide oxidation into ferrihemoglobin, so as to protect
Hinder the oxygen carrying capacity of hemoglobin.Vitamin C provides H for glutathione, so that the constantly GSH in added body, makes its performance
Oxidation resistant effect.
Many studies have shown that internal GSH content, which declines, easily makes damaged membrane, this is relevant with lipid peroxidation.Cell
Unrighted acid on film is vulnerable to the oxidation of the materials such as free radical, peroxide and forms MDA, so that
Damaged membrane.GSH can directly remove free radical, prevent unrighted acid to be oxidized.On the other hand, GSH can suppress
The generation of lipid peroxidation.Past research thinks that the peroxide of lipid can be reduced into unrighted acid by GSH, this
Process is carried out in the presence of glutathione peroxidase (GSH-Px).Vitamin C can be continuously replenished in body
GSH, played a role jointly in anti-lipid peroxidation with GSH.
3.2 promote collagen synthesis
Vitamin C the research collagen (collagen) in terms of collagen synthesis be contain in human body it is most abundant
Protein, be primarily present in the positions such as human body skin, bone, tooth, internal organ (including the heart, stomach, blood vessel), its function is to maintain
The form and structure of skin and histoorgan, and repair the important source material material of each injury tissue.Collagen includes a lot
Type, have I, II, III, IV type etc., wherein I type has accounted for more than the 90% of whole collagen contents.Vitamin C is in collagen egg
Played an important role during white synthesis.Research shows that increase vitamin C can make I, and III collagen type mRNA's contains
Amount rise, beneficial to the expression of collagen gene, can strengthen I, III type mRNA stability.In addition, ascorbic content liter
Height can suppress the expression of type Ⅳ collagen GFP.For effect of the vitamin C in collagen post-translational control, dimension life
Plain C is to maintain one of necessary co-factor of proline -4- hydroxylases (pmlyl-4-hygroxylase, PH) activity, and PH is in collagen
The proline on No. 4 C in polypeptide chain is hydroxylated into hydroxyproline in the building-up process of albumen.Hydroxyproline is to collagen
Folding, maintain tertiary structure have the function that it is important.Be deficient in vitamin C, and PH will lose its activity, and collagen just can not be just
Really fold.Hydroxyproline in other collagen peptide chain is to pass through lysyl hydroxylase by proline
The effect of (lysylhydroxylase, LH) and formed, the activity of the enzyme is also required to vitamin C.Hydroxylysine is in viscose
Original molecule interior energy forms stable hinge arrangement, and collagen is glycoprotein, and the residue of hydroxylysine is also the bound site of carbohydrate
Point.Hydroxylation reaction during collagen synthesis is extremely important, if serious consequence will be produced by lacking vitamin C, such as
Leukaemia.
3.3 anti-arteriosclerosis
Cholesterol (cholesterol) is widely present in animal body, especially with the abundantest in brain and nerve fiber,
Content in kidney, spleen, skin, liver and bile is also very high.Cholesterol is indispensable important substance in animal tissue cell, it
The formation of cell membrane is not only involved in, and is the raw material of synthetic bile acid, vitamin D and steroid hormone.But excessive courage
Sterol will cause to have a strong impact on to body, such as gall stone, atherosclerosis.Vitamin C has in the metabolism of cholesterol
Vital effect.By studying vitamin C to being sent out in skin fibroblasts LDL receptor (LDL-R) activity
Existing, vitamin C can strengthen the expression of LDL-R genes.2/3 cholesterol is present in LDL in human body, LDL degraded be by
What the LDL-R on cell membrane was mediated.LDL-R is combined with LDL and is mediated LDL then LDL is in liver intracellular metabolite by cell endocytic
Fall, cholesterol metabolic forms bile acid and excreted.Cholesterol is changed into bile acid first by annulus hydroxylating, then side
Chain, which decomposes, can form bile acid, and wherein hydroxylation procedures need vitamin C, and courage can not be changed into by lacking vitamin C cholesterol
Juice acid.In the building-up process of cholesterol, 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase) is synthesis
An important enzyme during cholesterol, the activity of the suppressible HMG-CoA reductase of vitamin C, so as to suppress cholesterol
Synthesis.Vitamin C adjusts content of the cholesterol in body jointly by decomposing and synthesizing two approach, so as to reduce excess
Cholesterol endangered to caused by body, played an important role in antiatherosclerosis.
3.4 Vitamin Cs disease
Scurvy (scurvy) is due to the disease caused by C that is deficient in vitamin.People are known that this before the centuries
Disease, but because people at that time are unclear for scorbutic pathogenic factor, so the death rate is very high.In 18th century, bad blood
Disease is mainly in area of the sailor of ocean navigation, the soldier of long-term tired war, long-term lacking fresh fruit and vegetables etc..Scotland sea
Army's medical officer's James's woods moral finds that this disease is relevant with diet, and explorer James Cook, England is further discovered that to drink tangerine
After sub- juice, lemon juice, scurvy can be treated and prevented, but was not aware that it is that what material acts at that time.Until 1912
Scientist in Poland Casimir Feng Ke illustrates the concept of vitamin, people just determine the disease be due to be deficient in vitamin C and
It is caused.Scorbutic clinical manifestation mainly reflects the important function that vitamin C plays during collagen synthesis.It is special
Fixed tissue and the fragility of the capillary mainly proline dihydroxylation process during collagen synthesis are obstructed, so as to cause
Collagen can not synthesize.Collagen is attributed to connective tissue, is the important component of bone and capillary etc., and connective group
Knit be wound healing the first step, so collagen synthesis, which is obstructed, just occurs capillary breakage, hemostasis, purpura, gum
The symptoms such as bleeding, wound healing delay, poor bone quality, arthralgia, serious conditions can then cause death.Vitamin C is collagen
The co-factor of proline hydroxylase, hydroxyproline can not be formed by lacking vitamin C and may result in proline, influence collagen
Synthesis.Appropriate vitamin C can, which is supplemented, for scorbutic treats scurvy.
3.5 antitumaous effect
Cancer (cancer) is the first big cause of the death of mankind nowadays, and treating cancer is also a problem in the world, vitamin C
Also there is important meaning in terms of anti-curing cancers.The reason for inducing cancer is a lot, including gene mutation, damage of the free radical to cell
Wound, induction of physical chemical factor etc..Cornell University professor C.Y.Lee etc. has found that vitamin C can eliminate hydrogen peroxide, prevents
The only canceration of cell.Wherein suppression breach connecting points intercellular communication (gap-junction of the vitamin C to peroxide induced
Intercellular communication, GJIC) there is prevention effect.GJIC be maintain normal cell growth necessary to, with
Suppress the process that cancer occurs especially with initiation tumour to be closely related.Hydrogen peroxide is a kind of tumor initiator, and it is by changing
Become a kind of specific proteins-connexin 43 (connexin43) to suppress GJIC, so as to the canceration of inducing cell.When with
When vitamin C handles rat liver epithelial cell, researcher has found that the GJIC inhibitory action that hydrogen peroxide induces is prevented.
Nitrite (nitrite) is universally acknowledged carcinogen, can induce kinds cancer.Research shows, nitrite can be with
With body intracellular metabolite caused by amines formed inferior ammonium nitrate and induce cancer, vitamin C can block the approach, so as to press down
The generation of cancer processed.Ultraviolet radioactive can cause DNA damage, induce the canceration of cell.By studying various concentrations vitamin C pair
Found in the influence of the ultraviolet damages of DNA, the vitamin C less than 0.35mmol/L has obvious to the DNA damage of induced by ultraviolet irradiation
Protective effect and protecting effect become better and better with the increase of its concentration, protecting effect is optimal during 0.35m mol/L.Work as dimension
When raw plain C concentration is higher than 0.35m mol/L, vitamin C not only promotes DNA damage on the contrary without protection, and DNA is damaged
Degree increase with the increase of vitamin C concentration.The DNA aqueous solution passes through ultraviolet irradiation meeting in the case of aerobic
Free radical is produced, free radical can destroy DNA, make its double-strand break, and space structure changes.Vitamin C can be removed certainly
By base, protection DNA exempts from the destruction of free radical.
4 wheat oligopeptides
In recent years, the functional character of biologically active peptide and application cause the extensive concern of people, and research is pointed out, oligopeptide
It is more easy to digest than protein, absorb also faster than Amino Acid Absorption speed.Oligopeptide need not digest after entering alimentary canal, Ke Yizhi
Absorption is connect, transport speed is fast, power consumption is low, is not easy saturation, while can eliminate the absorption competition with free amino acid, and this is former egg
Not available for white matter and amino acid.China is Wheat Production big country, and wheat resource is enriched, and biologically active peptide is extracted from wheat
Become focus of concern.Wheat oligopeptide derives from wheat gluten, and cost is low, processing characteristics is good, is a kind of excellent
Nutritious supplementary pharmaceutical, there is great market development value.Wheat oligopeptide is using Gluten as raw material, by orienting digestion
And the micromolecule polypeptide class mixture that specific small peptide isolation technics obtains, main component is made up of 2~6 amino acid moleculars
Small peptide, bitter, good water solubility, stably dispersing, easily absorb, bioactivity is strong etc..Amino acid content is balanced in wheat oligopeptide,
Almost as wheat gluten, the content highest of its Glutamic Acid is most of to exist in the form of glutamine.
It is 4.1 anti-oxidant
Wheat oligopeptide is a kind of anti-oxidation peptide, can remove interior free yl well, protects the oxidative stress of cell.
Wheat oligopeptide can strengthen activities of antioxidant enzymes, anti-lipid peroxidation, radicals scavenging in acceleration bodies, while relevant external
Anti-oxidant experiment shows that wheat oligopeptide has external reducing power.On the anti-oxidant principle of wheat oligopeptide, have both at home and abroad not
Same viewpoint.The power of the antioxidation activity of peptide is relevant with the Nomenclature Composition and Structure of Complexes of certain amino acid.Research finds that anti-oxidation peptide is preferential
Combined with fatty acid profile, stop free chain reaction, so as to anti-lipid peroxidation.Wheat oligopeptide it is anti-oxidant
Function contains hydrophobic grouping (Glu, Leu, Tyr) with it or basic amino acid (His, Arg, Lys) is relevant.There is research to point out, it is small
Wheat oligopeptide contains the abundant amino acid with antioxidation activity, such as glutamic acid, proline, leucine, methionine and group ammonia
Acid etc..Due to the complexity of human physiological activity, the specific mechanism of wheat oligopeptide antioxidation activity need further to grind
Study carefully.
4.2 regulation immunologic functions
The immunocompetence of wheat oligopeptide has been confirmed, with Alcalase hydrolysis by novo wheat glutens, hydrolysis
Contain the active peptide for stimulating mouse lymphocytes in vitro proliferation function in thing.Correlative study reported its mechanism, wheat
Oligopeptide contains abundant glutamine, can stimulate the propagation of body lymphocyte, strengthens the phagocytic function of macrophage, improves
Body anti-infection ability, effectively improves immunity of organisms.The immunocompetence of wheat oligopeptide may contain hydrophobic amino with it
Acid or basic amino acid are relevant.
4.3 hypotensive
Wheat gluten caused wheat oligopeptide after protease hydrolytic contains angiotensin converting enzyme (ACE), and ACE is
Can catalyzing hydrolysis angiotensinⅠ change into hypertensive factor --- angiotensinⅡ, can also decompose that depressor is slow to swash
Peptide, it is set to lose activity.Wheat oligopeptide can play a part of regulating and controlling blood pressure by suppressing ACE activity.There is research in acidity
Under the conditions of utilize protease hydrolytic wheat glutenin, obtained the tripeptides with ACE inhibitory activity, and use solid-phase synthesis
This peptide has been synthesized, and equally there is ACE inhibitory activity.It is another to there is researcher to produce hypotensive with enzymolysis Wheat Germ Protein method
Peptide.Matsul T extract blood pressure lowering peptide using 5 kinds of protease direct hydrolysis wheat-germ meals.
4.4 regulation blood cholesterol levels
Wheat oligopeptide has the function that to adjust blood cholesterol levels.Existing research is acted on the norcholesterol of soybean oligopeptide
Study it is more, it is relatively fewer to the norcholesterol Effect study of wheat oligopeptide.There is research low in the wheat of observation various concentrations
Poly- peptide is drawn a conclusion after the influence to HepG2 cell lines cholesterol metabolic, it is believed that the wheat oligopeptide of various concentrations is equal
The intracellular LDLR mRNA level in-sites of HepG2 can be lifted and reduce HMGCR mRNA level in-sites, so as to play a part of reducing cholesterol.
4.5 analgesic activity
Wheat oligopeptide has opioid activity, can play analgesic activity, is found that in 1979 with pepsin water
Wheat gluten is solved, the peptide matters (External irradiation) with opioid activity can be obtained, can effectively adjust nerve, analgesia is played and makees
With.
4.6 other effects
Wheat oligopeptide also has antiallergy, anticancer isoreactivity.Research confirms that there is wheat peptide higher antiallergy to live
Property, correct quick matter smoked plum there is stronger inhibitory action.Research points out that the glutathione peroxidase contained in wheat peptide can urge
Change reduction organic peroxide, internal chemical carcinogen is lost toxicity, and then play the effect of certain pre- anti-cancer.It is small
In wheat oligopeptide enrich glutamine, be excellent glutamine replenishers, have regulation blood glucose, it is antifatigue, protection brain,
Strengthen the biological functions such as memory, regulation gastrointestinal function.
5 maize oligopeptides
Maize oligopeptide peptide is a series of product of the zein after enzymolysis, and it is by a large amount of small-molecular-weight small peptide groups
Into (general molecular weight concentrates on less than 1000), but the oligomeric peptide activity of this small-molecular-weight small peptide composition is high, can be supplied to
Special population (such as baby's digestive function is unsound, the enteron aisle such as the elderly digestion and absorption function decline crowd) enteral nutrition, to art
Rehabilitation also has auxiliary treatment functio afterwards.
5.1 reduce blood pressure
Angiotensin converting enzyme (ACE) is to cause the elevated basic substance of blood pressure, and it makes vessel retraction, causes blood pressure liter
Height, and corn peptide then has the active function for suppressing angiotensin converting enzyme, mitigates vascular tone, produces antihypertensive effect.
Similarly, corn peptide also can preventing hypertension generation but have no side effect to blood pressure normal population.
5.2 sobering-up functions
Corn peptide can suppress absorption of the stomach to alcohol, increase the activity of internal alcohol dehydrogenase and acetaldehyde dehydrogenase, promote
The metabolism and discharge of alcohol in vivo, have and suppress alcoholism effect.Corn peptide can be by improving the alanine in blood
Stable NAD+, the concentration of alcohol being effectively reduced in blood are produced with the concentration of leucine.The scholar of foreign study corn peptide
Corn peptide is more keen to.Such as Japanese scholars M.Yamaguchi etc. is by successively filling food corn to original hypertensive rat
Peptide and ethanol, compare check sample, finding the content of ethanol in blood and its oxidation product acetaldehyde all substantially reduces.Same knot
Fruit is also confirmed in human experimentation, therefore can be used as product of sobering up.
5.3 antioxidation
Corn peptide has very strong inoxidizability, and its inoxidizability is easily removed super similar to superoxide dismutase, corn peptide
Oxygen anion free radical and hydroxyl radical free radical, and suppress the generation of cell and tissue lipid peroxidization.
5.4 other:Maize oligopeptide also has fat-reducing, antifatigue, liver protection, improves the functions such as immunity of organisms.
6 yeast-beta glucan
Beta glucan (β-glucan) is a kind of homopolymer of glucose, is largely present in microorganism, plant and animal
In vivo.The glucose unit of the beta glucan of separate sources links together in a different manner, poly- formed with bioactivity
Compound.In the 1940s, be found that has a kind of active material in yeast cells, it has Pillemer and Ecker etc.
The effect of immunostimulation.Di Luzio and Riggi just determines that this active material is exactly β -1,3- Portugals to or so nineteen sixty
Glycan.This several years many experimental study all shows that the beta glucan being highly profitable to the physiological function of human body can be significantly
Hypoglycemic, reducing blood lipid, immunity etc. can also be improved, so the exploitation and research of beta glucan are very burning hot.Biology
Active highest beta glucan is exactly yeast beta-dextran.Yeast is a kind of important food industry microorganism, glucan, albumen
Matter and mannosan be respectively the innermost layer of yeast cell wall to outermost layer, wherein the glucan positioned at innermost layer is exactly homogeneous
Active polysaccharide, the beta glucan in yeast is the linear backbone and β -1 of the connected D-Glucose composition of 3 keys by β -1,6 keys
Branch be connected with trunk composition, yeast beta-dextran compares its branch head [3] with general fungi, and yeast beta-dextran exists
Huge commercial value, such as food, medicine, cosmetics and aquaculture are suffered from many industries.
6.1 enhancings are immune
The most basic function of beta glucan is exactly immunoregulation effect, and internal and external experimental study is found,
Beta glucan can be greatly improved with stimulating innate immunity system so as to reach the ability of resistance bacterium, fungi and virus etc..β-
Glucan by activating T cell, macrophage and NK, be able to can also stimulate T lymphocytes differentiation and
Activation, the change of simultaneously activated pathway complement is influenceed, be finally reached the effect of enhancing body cell and humoral immunity.
The effect of 6.2 pairs of stomach
Because not having the enzyme of degraded beta glucan in human body, they play the role of natural trophic fiber.Research
Show, the diet of high microsteping can reduce cholesterol, and reduce chronic disease and the cardiopathic incidences such as arthritis.When β-
Glucan enters oral cavity, will start water swelling.Water miscible beta glucan can allow again food stickiness increase, the speed of gastric emptying
Degree slows down, and then satisfaction when adding dining and postprandial satiety.Found after having fed the fiber of solubility to rat,
Delayed gastric emptying is not only relevant with the stickiness of beta glucan, and relevant with the metabolite short chain fatty acids in colon.Pass through
Animal experiment research finds that the dietary fiber of beta glucan can increase the haulage time of enteron aisle, there is the work for slowing down intestinal absorption
With.It has also been found that, because the high viscosity that water miscible dietary fiber can be formed, enteron aisle can be not only neutralized in clinical test
Contractile motion, so as to cause its wriggling slack-off;Cholecystokinin (CCK) release can also be stimulated, CCK has stimulation small bowel peristalsis
Effect.In addition, the SCFA that soluble food fiber ferments to obtain in large intestine can also stimulate intestinal contraction.
6.3 promote wound healing effect
Its essence of the reparation of wound is the reparation of homeostasis, is an extremely complex physiology course.Normal condition
Under, the reparation of wound is to need the macrophage between different phenotype cells, fibroblast, keratinocyte and wound life
The mutual layout effect such as the long factor, stromatin and matrix repair enzyme.Also pertinent literature shows, gives part or whole body
Beta glucan can accelerate the healing rate of wound, and its mechanism is the infiltration for increasing macrophage in site of injury, so as to promote meat
The growth of bud and the deposition of collagen, while strengthen the tensile strength of injury.
6.4 blood coagulation resisting function
The sulfate that people have synthesized the polysaccharide of various structures determination is to find the substitute of heparin.By testing,
The sulfate of beta glucan shows significant anticoagulant active.Researcher to the structure-activity relationship of beta glucan sulfate, its
Degree of molecular weight and sulfation etc. finds that the anticoagulant deciding factor of beta glucan is just after having done experimental study
It is the basic structure of polysaccharide and the pattern of sulfation.The mode of action of beta glucan is different from heparin, and they are against certainly
The unique structure of body, antithrombase AT-III is adjusted, it is suppressed that prothrombin a and Xa activity, reach specific
The different phase for disturbing coagulation process.
6.5 antitumor action
Research is found, although many polysaccharide all have antineoplastic action, the β studied at present-(1,3) glucan
There is obvious advantage on antitumor activity with β-(Isosorbide-5-Nitrae) glucan, and related such polysaccharide.Beta glucan is anti-swollen simultaneously
There is very close relationship between knurl and its immunization, because polysaccharide body can promote cytohormone IL-1, IL-2
Secretion, they can increase the number of T cell, strengthen its action function, can also increase the attacking ability of internal macrophage
By force, abnormal and death of neoplastic cells is made, so there is the effect of cancer-resisting.
6.6 radioresistances and antioxidation
Internal free radical is removed, allows macrophage by, from being attacked by free radical, making macrophage still after radiating
Can normally be played a role the effect of being beta glucan.Pathchen ML etc. find, water miscible glucan can make by cobalt-
Cell recovery from illness after 60 induction radiation is accelerated.Mouse through overshoot through β-treatment of (1,3) glucan, recovery can be significantly improved
Ability, strengthen the vigor and splenocyte quantity of its marrow.Free radical scavenger in organism, there is positive work for anti-oxidant
SOD.The water miscible yeast β of various dose-(1,3) glucan acts on test mice, SOD vigor in its serum
It can increase with the increase of dosage, research is found, it, which presents dosage and effect, positively related relation, illustrates water
The yeast β of dissolubility-(1,3) glucan has the effect for removing free radical well, and drug administration by injection effect compares gastric infusion
Effect will get well.
7 xylo-oligosaccharides
Xylo-oligosaccharide is also referred to as wood oligose, is the β-Isosorbide-5-Nitrae for passing through endo-xylanase hydrolyzed xylan as substrate using xylan
Obtained from glycosidic bond using xylobiose, xylotriose as main component xylo-oligosaccharide mixture.The sugariness of xylobiose is equivalent to sugarcane
The 30% of sugar, and the sugariness of xylo-oligosaccharide is pure, without peculiar smell.Xylo-oligosaccharide has the work(of very strong propagation beneficial bacteria of intestinal tract
Can, there is high selectivity cultivation effect to probiotics such as Bifidobacterium, lactic acid bacterias, but to Escherichia coli, enterococcus, fusiform gemma bar
The pathogens such as bacterium then have obvious inhibitory action.Experiment in vitro shows, Bifidobacterium (such as bifidobacterium longum, bifidobacterium adolescentis
And bifidobacterium infantis etc.) using xylobiose, xylotriose or xylo-oligosaccharide using xylobiose as main component;Lactic acid bacteria and
Other probiotics can also ferment using xylo-oligosaccharide, but the pathogen such as Escherichia coli, enterococcus and clostridium can not
Utilize xylo-oligosaccharide.In addition, rat experiment in vivo shows, xylo-oligosaccharide also has high selectivity propagation in enteron aisle to Bifidobacterium
It effect, can not only breed its quantity, and its time-to-live can be extended.
Xylo-oligosaccharide is difficult to be decomposed by human consumption, and saliva, gastric juice, pancreatic juice and intestinal fluid etc. can hardly all decompose oligomeric
Xylose.Its energy value is approximately zero, can be played a role in low-energy food.Meet that those like sweets to carry on a shoulder pole again to greatest extent
The requirement of the heart person of getting fat.Also it is available for diabetes patient, adiposis patient and hyperglycemia patient to eat.Improve in addition, xylo-oligosaccharide has
The function of stool.The moisture in stool is added after intake xylo-oligosaccharide, the form of stool can be changed, so as to prevent constipation
Appearance.Xylo-oligosaccharide is also used as antioxidant, can prevent oxidative stress, anaemia, artery sclerosis, diabetes, sclerotin
Loose and certain cancers.Xylo-oligosaccharide is also proved to have reducing blood lipid, antibacterial, anti-inflammatory, antianaphylactic effect.
Case study on implementation 1
WPC (65.6%), white fungus powder (10.9%), acerola concentrate powder (10.9%), wheat oligopeptide
(3.3%), maize oligopeptide (3.3%), yeast-beta glucan (1.1%), xylo-oligosaccharide (4.3%), steviol glycoside
(0.6%).
This example be conventional nutrient support, be adapted to various Hypoproteinemias, digestion and absorption function decline, eating difficulties and
Poor appetite crowd.Steviol glycoside is added, assigns the appropriate sweet taste of product, mouthfeel is more preferably.
Case study on implementation 2
WPC (60%), white fungus powder (16%), acerola concentrate powder (11%), wheat oligopeptide (3.5%), jade
Rice oligopeptide (2.8%), yeast-beta glucan (1.4%), xylo-oligosaccharide (5.3%).
This example is adapted to the too high crowd's generation meal of fat or body fat, that is, provides the nutrition of abundance, the intake of and can control fat.
Case study on implementation 3
WPC (65.6%), white fungus powder (10.9%), acerola concentrate powder (10.9%), wheat oligopeptide
(3.3%), maize oligopeptide (3.3%), yeast-beta glucan (1.1%), xylo-oligosaccharide (4.3%), compounding vitamin, mineral
Element, steviol glycoside (0.6%).
This example is compound compatibility multivitamin (axerophtholum aceticum, vitamin using inventive formulation as core component
D3, dl- α-D-α-tocopherol acetate, thiamine hydrochloride, riboflavin, puridoxine hydrochloride, cyanocobalamin, niacinamide, folic acid, D-VB5 calcium),
Magnesium carbonate, sodium iron ethylene diamine tetra acetate, zinc gluconate, calcium monohydrogen phosphate, full nutrition class product is made, other foods can be substituted completely
Thing, supplement high-quality protein, carbohydrate, vitamin, mineral element, and provide it is various contribute to strengthen immunity, reduce sense
The health factor of dye and complication risk.
The preferred embodiments of the present invention are the foregoing is only, are not intended to limit the invention, for the skill of this area
For art personnel, the present invention can have various modifications and variations.Within the spirit and principles of the invention, that is made any repaiies
Change, equivalent substitution, improvement etc., should be included in the scope of the protection.
Claims (6)
- A kind of 1. compound oligomeric peptide nutrient powder of WPC, it is characterised in that:It is main to include following original in parts by weight Material:55~70 parts of WPC, 7~12 parts of white fungus powder, 7~12 parts of acerola concentrate powder, 2~6 parts of wheat oligopeptide, corn 2~6 parts of oligopeptide, 0.5~1.7 part of yeast-beta glucan, 3~6 parts of xylo-oligosaccharide.
- 2. the compound oligomeric peptide nutrient powder of WPC according to claim 1, it is characterised in that:Mainly include as follows Raw material by weight percentage:WPC 65.6%, white fungus powder 10.9%, acerola concentrate powder 10.9%, wheat are low Poly- peptide 3.3%, maize oligopeptide 3.3%, yeast-beta glucan 1.1%, xylo-oligosaccharide 4.3%, steviol glycoside 0.6%.
- 3. the compound oligomeric peptide nutrient powder of WPC according to claim 1, it is characterised in that:Mainly include as follows Raw material by weight percentage:WPC 60%, white fungus powder 16%, acerola concentrate powder 11%, wheat oligopeptide 3.5%th, maize oligopeptide 2.8%, yeast-beta glucan 1.4%, xylo-oligosaccharide 5.3%.
- 4. the compound oligomeric peptide nutrient powder of WPC according to claim 1, it is characterised in that:Mainly include as follows Raw material by weight percentage:WPC 65.6%, white fungus powder 10.9%, acerola concentrate powder 10.9%, wheat are low Poly- peptide 3.3%, maize oligopeptide 3.3%, yeast-beta glucan 1.1%, xylo-oligosaccharide 4.3%, compounding vitamin, mineral member Element, steviol glycoside 0.6%.
- 5. the compound oligomeric peptide nutrient powder of WPC according to claim 1 or 2 or 3, it is characterised in that:Described WPC is that whey is passed through into native whey protein concentrate made of low temperature ultrafiltration and spray drying.
- 6. the compound oligomeric peptide nutrient powder of WPC according to claim 1 or 2 or 3, it is characterised in that:Described Wheat oligopeptide is the micromolecule polypeptide class using Gluten as raw material, by orienting digestion and the acquisition of specific small peptide isolation technics Mixture, main component are the small peptides being made up of 2~6 amino acid moleculars.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710934686.5A CN107890117A (en) | 2017-10-10 | 2017-10-10 | A kind of compound oligomeric peptide nutrient powder of WPC |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710934686.5A CN107890117A (en) | 2017-10-10 | 2017-10-10 | A kind of compound oligomeric peptide nutrient powder of WPC |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107890117A true CN107890117A (en) | 2018-04-10 |
Family
ID=61803496
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710934686.5A Pending CN107890117A (en) | 2017-10-10 | 2017-10-10 | A kind of compound oligomeric peptide nutrient powder of WPC |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107890117A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109329948A (en) * | 2018-12-05 | 2019-02-15 | 北京斯利安药业有限公司 | A kind of composition and its application with strengthen immunity function |
CN112890066A (en) * | 2021-03-16 | 2021-06-04 | 江西省科学院生物资源研究所 | Solid beverage capable of regulating blood fat, resisting fatigue and enhancing immunity and application thereof |
CN114916677A (en) * | 2022-04-18 | 2022-08-19 | 沈阳药大生物科技有限公司 | Oligopeptide composition for improving cell health condition |
CN115521963A (en) * | 2022-10-28 | 2022-12-27 | 华南理工大学 | Glutamine peptide and preparation method and application thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101496579A (en) * | 2008-01-28 | 2009-08-05 | 中国食品发酵工业研究院 | Special diet and foodstuffs formula containing small peptide for tumor patient |
CN104605353A (en) * | 2015-01-27 | 2015-05-13 | 南阳市新天地生物科技有限公司 | Formula food suitable for being eaten by tumor patients after operation and preparation method of formula food |
CN105077270A (en) * | 2015-07-16 | 2015-11-25 | 上海冬泽特医食品有限公司 | Nutrient supplemented composite powder as well as preparation method and use thereof |
CN107173732A (en) * | 2017-05-31 | 2017-09-19 | 江苏朸健生命科技发展有限公司 | It is a kind of suitable for composite nutrition powder of tumors of nutrients and preparation method thereof |
-
2017
- 2017-10-10 CN CN201710934686.5A patent/CN107890117A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101496579A (en) * | 2008-01-28 | 2009-08-05 | 中国食品发酵工业研究院 | Special diet and foodstuffs formula containing small peptide for tumor patient |
CN104605353A (en) * | 2015-01-27 | 2015-05-13 | 南阳市新天地生物科技有限公司 | Formula food suitable for being eaten by tumor patients after operation and preparation method of formula food |
CN105077270A (en) * | 2015-07-16 | 2015-11-25 | 上海冬泽特医食品有限公司 | Nutrient supplemented composite powder as well as preparation method and use thereof |
CN107173732A (en) * | 2017-05-31 | 2017-09-19 | 江苏朸健生命科技发展有限公司 | It is a kind of suitable for composite nutrition powder of tumors of nutrients and preparation method thereof |
Non-Patent Citations (3)
Title |
---|
潘兴昌等: "食源性低聚肽与特殊膳食食品的开发", 《营养与食品-健康中国高级论坛II论文集》 * |
阎世英: "《酵素决定健康》", 31 January 2016, 北京医药科技出版社 * |
齐玉梅等: "《特殊医学用途配方食品临床应用参考目录》", 31 August 2017, 中国医药科技出版社 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109329948A (en) * | 2018-12-05 | 2019-02-15 | 北京斯利安药业有限公司 | A kind of composition and its application with strengthen immunity function |
CN109329948B (en) * | 2018-12-05 | 2022-04-01 | 北京斯利安药业有限公司 | Composition with function of enhancing immunity and application thereof |
CN112890066A (en) * | 2021-03-16 | 2021-06-04 | 江西省科学院生物资源研究所 | Solid beverage capable of regulating blood fat, resisting fatigue and enhancing immunity and application thereof |
CN114916677A (en) * | 2022-04-18 | 2022-08-19 | 沈阳药大生物科技有限公司 | Oligopeptide composition for improving cell health condition |
CN115521963A (en) * | 2022-10-28 | 2022-12-27 | 华南理工大学 | Glutamine peptide and preparation method and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108112996B (en) | Nutritional composition for controlling hyperglycemia and improving immunity of type 2 diabetes mellitus people | |
CN101473953B (en) | Fabricated food for cleaning blood and expelling toxin as well as method for processing the same and application | |
CN108685100B (en) | Formula and preparation method of composite short peptide powder | |
CN101077143A (en) | Tatol nutrient green health care beans flour noodle series such as fine dried noodles and instant noodles and its manufacturing method | |
CN111670997A (en) | Preparation method of immune-enhancing compound protein peptidase hydrolyzed liquid, immune-enhancing compound protein peptide beverage and preparation method thereof | |
CN110771825A (en) | Comprehensive nutrition powder for reducing fat, blood sugar, blood pressure and blood fat and preparation method thereof | |
CN107890117A (en) | A kind of compound oligomeric peptide nutrient powder of WPC | |
KR101539382B1 (en) | Food composition for improvement of bowel function and relief of constipation | |
CN102488278A (en) | Composite fungus nutrient solution with bifunctional health care effect | |
CN104207150A (en) | Oral liquid containing soybean peptides and fungi polysaccharides and preparation method thereof | |
CN106578801A (en) | Comprehensive enzyme powder with hypoglycemic effect and preparation method thereof | |
CN104605353A (en) | Formula food suitable for being eaten by tumor patients after operation and preparation method of formula food | |
CN106360739A (en) | Composition capable of adjusting blood pressure, reducing blood sugar and complementing nutrition | |
CN106858595A (en) | One kind burn tailored version clinical nutrition formula and preparation method thereof | |
CN105380271A (en) | Additive-free full grain mung bean recombined nutrition powder and production method thereof | |
CN101569410A (en) | Special meal nutritional foods used by tumor patients | |
CN107279978A (en) | A kind of special medicine purposes formula food suitable for tumour patient | |
JP2002272414A (en) | Nutritional supplementary composition for inhibiting large vowel cancer and method for producing the same | |
CN109329902A (en) | A kind of leukemia of children tailored version clinical nutrition formula and preparation method thereof | |
CN111543605A (en) | Comprehensive nutrition powder for people with hypertension, hyperlipidemia and obesity | |
CN108308597A (en) | A kind of malnutrition tailored version clinical nutrition formula and preparation method thereof | |
CN108576827A (en) | Peri-operation period nutraceutical | |
CN108783465A (en) | A kind of nutrition formula product with oncotherapy function | |
CN108378296A (en) | Peri-operation period nutraceutical | |
CN106136235A (en) | A kind of tumour patient special medicine purposes formula food |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180410 |